Why, 20 years later, have the US and the EU agreed on another go at mutual recognition for drug GMP inspections?
At first blush, the timing couldn’t be any worse.
Why Now Is The Right Time For Mutual Recognition
20 years later, signs that this time the US EU mutual recognition agreement won’t fizzle.
More from Compliance
More from Pink Sheet
• By
The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.
• By
In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.
• By
The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.